ACETYLCYSTEINE

/static/temp/default.svg

Search structure


Trade Names	ACETADOTE ACETYLCYSTEINE CETYLEV MUCOMYST MUCOSIL-10 MUCOSIL-20
Synonyms	5052 A-cys Acc-600 Acetadote Acetyl cysteine Acetylcysteine Airbron Broncholysin Cetylev En-cys Fabrol Fluimicil Fluimucetin Fluimucil Fluimucil 600 Fluimucil long Fluimucil n Ilube Mercapturic acid Mucomyst Mucosil Mucosil-10 Mucosil-20 N-Acetyl-L-Cysteine N-acetyi-l-cysteine N-acetyl-l-cysteine NSC-111180 Oristar nalc Oronac 600 Parvolex RK-0202 Respaire Respi-nac Rk-0202 Siran Solmucol Syntemucol Tixair Yournac
Status
Molecule Category	Free-form
ATC	R05CB01 S01XA08 V03AB23
UNII	WYQ7N0BPYC
EPA CompTox	DTXSID5020021


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	PWKSKIMOESPYIA-BYPYZUCNSA-N
Smiles	CC(=O)N[C@@H](CS)C(=O)O
InChI	InChI=1S/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)/t4-/m0/s1

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C5H9NO3S
Molecular Weight	163.2
AlogP	-0.49
Hydrogen Bond Acceptor	3.0
Hydrogen Bond Donor	3.0
Number of Rotational Bond	3.0
Polar Surface Area	66.4
Molecular species	ACID
Aromatic Rings	0.0
Heavy Atoms	10.0

Pharmacology

Mechanism of Action	Action	Reference
Glutathione precursor	None	DailyMed FDA DailyMed

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides	-	-	-	-	82
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC22 family of organic cation and anion transporters	-	-	-	-	16

Assay Description	Organism	Bioactivity	Reference
Inhibition of 4-(4-(dimethylamino)styryl)-N-methylpyridinium uptake at human OCT1 expressed in HEK293 cells at 100 uM by confocal microscopy	Homo sapiens	15.5 %
Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	Cricetulus griseus	82.21 %
Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM	Cricetulus griseus	89.21 %
Antioxidant activity in human SH-SY5Y cells assessed as inhibition of t-BuOOH-induced intracellular ROS formation at 500 uM after 30 mins by dihydroethidium-based spectrofluorometric analysis relative to control	Homo sapiens	35.0 %
Antioxidant activity in human SH-SY5Y cells assessed as inhibition of amyloid beta (25 to 35)-induced intracellular ROS formation at 500 uM after 3 hrs by dihydroethidium-based fluorescence microscopic analysis relative to control	Homo sapiens	35.0 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging	Homo sapiens	-5.13 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	14.12 %		SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate	Severe acute respiratory syndrome coronavirus 2	26.89 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.16 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.43 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.16 %		Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging	Chlorocebus sabaeus	0.43 %

Related Entries

Cross References

Resources	Reference
ChEBI	28939
ChEMBL	CHEMBL600
DrugBank	DB06151
DrugCentral	66
FDA SRS	WYQ7N0BPYC
Human Metabolome Database	HMDB0001890
Guide to Pharmacology	10945
KEGG	C06809
PDB	SC2
PharmGKB	PA448033
PubChem	12035
SureChEMBL	SCHEMBL5292
ZINC	ZINC000003589203

CONTENTS

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).